CRISPR Therapeutics Q2 Revenue Miss Sends Stock Price Tumbling

CRISPR Therapeutics (CRSP) reported disappointing Q2 2025 results, with a revenue miss of $5.6 million and a net loss per share of $2.40, up 61% YoY. Analysts forecast a one-year average price target of $80, suggesting a 34.26% potential upside. GuruFocus' GF Value analysis estimates a 33% downside potential from the current stock price.

CRISPR Therapeutics (CRSP) reported its second-quarter 2025 financial results, revealing a significant revenue miss and a substantial increase in net loss per share. The company reported a net loss of $2.40 per share, up 61% year-over-year (YoY), and revenue of $0.89 million, falling short of the Zacks Consensus Estimate of $6.6 million [1]. The increased loss was primarily due to a $96.3 million payment to Sirius Therapeutics as part of a strategic collaboration agreement [1].

Despite the financial challenges, CRISPR Therapeutics maintained a strong pipeline. The company reported that more than 75 authorized treatment centers were activated across regions where Casgevy, its CRISPR/Cas9 gene-edited therapy, is approved. The company also provided updates on its pipeline, including the development of next-generation CAR-T therapy candidates and in-vivo candidates targeting ANGPTL3 and lipoprotein(a) [1].

Analysts have responded to CRISPR Therapeutics' Q2 results with a mixed outlook. The current average analyst rating on the shares is "buy," with 17 "strong buy" or "buy" recommendations, 11 "hold" recommendations, and 1 "sell" or "strong sell" recommendation [2]. The median 12-month price target for CRISPR Therapeutics AG is $79.50, about 29.4% above its August 1 closing price of $56.09 [2].

H.C. Wainwright raised its price target on CRISPR Therapeutics to $80.00 from $65.00, maintaining a Buy rating on the stock [3]. This increase follows CRISPR's Q2 results, which showed CASGEVY sales totaling $30 million, a 114% increase compared to the first quarter of 2025 [3]. The company maintains a strong financial position, with more cash than debt on its balance sheet and a healthy current ratio of 16.6x [3].

GuruFocus' GF Value analysis estimates a 33% downside potential from the current stock price, suggesting that investors should be cautious about the company's financial health and growth prospects [3].

References:
[1] https://finance.yahoo.com/news/crsp-stock-down-huge-q2-155400470.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXEB53BD:0-crispr-therapeutics-q2-revenue-misses-estimates-net-loss-widens/
[3] https://ng.investing.com/news/analyst-ratings/crispr-therapeutics-stock-price-target-raised-to-80-by-hc-wainwright-93CH-2049810